Sinobioway Cell Therapy Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Tianjin China (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2015
NCT02728882
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Shanghai Sinobioway Sunterra Biotech | Sinobioway Cell Therapy Co., Ltd. | Tianjin Sinobioway Biomedicine Co.Ltd.

Active Ingredients

Drugs in Phase 4 Trials (2)

interferon alpha-2b (Intron-A) (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Phase 2 Trials (1)

cct301 (2 trials)

Drugs in Phase 1 Trials (1)

cd19 car-t cells (4 trials)

Drugs in Other Trials (2)

epcam car-t cells (2 trials)

gd2 car t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Herpangina (Phase 4)

Lymphoma (Phase 1)

Sarcoma (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 6